View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsHanulBnCLTD 配当と自社株買い配当金 基準チェック /06HanulBnCLTD配当金を支払った記録がありません。主要情報n/a配当利回り2.3%バイバック利回り総株主利回り2.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 14HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 289, jangmal-ro, gyeonggi-do, bucheon South Koreaお知らせ • Mar 05NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsOn March 4, 2024, NewGLAB Pharma CO.,LTD closed the transaction.お知らせ • Feb 23NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsNewGLAB Pharma CO.,LTD announced a private placement to issue 13,670,000 common shares at an issue price of KRW 500 per share for the gross proceeds of KRW 6,835,000,000 on February 22, 2024. The transaction included participation from new investors H&Y Holdings Co., Ltd. 5,600,000 shares, APIC Co., Ltd. 2,000,000 shares, Namu Invest Co., Ltd. 800,000 shares, Namhwa Corporation 400,000 shares and SLP Co. Ltd. 400,000 shares and individual investors OO Kim for 1,120,000 shares, OO Yoon 2,000,000 shares, OO 400,000 shares, LeeOO 400,000 shares and Seo OO 150,000 shares. The transaction has been approved by the shareholders of the company and is expected to closed on March 4, 2024. The securities are restricted to a hold period.Reported Earnings • Mar 18Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021)Full year 2022 results: ₩2,201 loss per share (further deteriorated from ₩1,662 loss in FY 2021). Revenue: ₩21.7b (down 26% from FY 2021). Net loss: ₩69.6b (loss widened 38% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 49% per year, which means it has not declined as severely as earnings.Buying Opportunity • Aug 24Now 25% undervaluedOver the last 90 days, the stock is up 38%. The fair value is estimated to be ₩17,476, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 56%.お知らせ • Apr 07NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmOn April 5, 2022, NewGLAB Pharma CO.,LTD closed the transaction.お知らせ • Mar 23NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in fundingOn March 22, 2021, NewGLAB CO.,LTD (KOSDAQ:A214870) closed the transaction.Reported Earnings • Mar 17Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩54.4b (down 43% from FY 2019). Net loss: ₩22.6b (loss widened 464% from FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 14NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in fundingNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 7 non-guaranteed private convertible bonds with bearer interest with for gross proceeds of KRW 9,230,000,000 on March 12, 2021. The transaction will include participation from Hyun-cheol Noh for KRW 3,230,000,000 and Seong-su Cho for KRW 6,000,000,000. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on March 22, 2024. The bonds are 100% convertible into 699,242 shares, representing 2.28%, at a fixed conversion price of KRW 13,200 per share. The conversion period starts from March 22, 2022 and ends on February 22, 2024. The subscription date is March 12, 2021 and the transaction is expected to close on March 22, 2021. The transaction has been approved by the company's board of directors. The bonds carry a hold period of one year.Is New 90 Day High Low • Feb 18New 90-day low: ₩10,900The company is down 15% from its price of ₩12,850 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 41% over the same period.Is New 90 Day High Low • Jan 27New 90-day low: ₩11,850The company is down 12% from its price of ₩13,500 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 57% over the same period.分析記事 • Dec 22The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...Is New 90 Day High Low • Nov 11New 90-day low: ₩12,750The company is down 4.0% from its price of ₩13,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 3.0% over the same period.お知らせ • Sep 29NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 6 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 35,000,000,000 on September 28, 2020. The transaction will include participation from returning investor DB Financial Investment Co.,Ltd., Investment Arm. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on October 20, 2023. The bonds are 100% convertible into 2,287,432 shares, representing 7.29%, at a fixed conversion price of KRW 15,301 per share. The conversion period starts from October 20, 2021 and ends on September 20, 2023. The subscription date is September 28, 2020 and the transaction is expected to close on October 20, 2020. The transaction has been approved by the company's board of directors.決済の安定と成長配当データの取得安定した配当: A214870の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: A214870の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場HanulBnCLTD 配当利回り対市場A214870 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A214870)n/a市場下位25% (KR)1.0%市場トップ25% (KR)3.8%業界平均 (Electronic)0.3%アナリスト予想 (A214870) (最長3年)n/a注目すべき配当: A214870は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: A214870は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: A214870の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A214870が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/01 11:55終値2025/03/28 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HanulBnC CO.,LTD 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jongsun ParkEugene Investment & Securities Co Ltd.
お知らせ • Mar 14HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 289, jangmal-ro, gyeonggi-do, bucheon South Korea
お知らせ • Mar 05NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsOn March 4, 2024, NewGLAB Pharma CO.,LTD closed the transaction.
お知らせ • Feb 23NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsNewGLAB Pharma CO.,LTD announced a private placement to issue 13,670,000 common shares at an issue price of KRW 500 per share for the gross proceeds of KRW 6,835,000,000 on February 22, 2024. The transaction included participation from new investors H&Y Holdings Co., Ltd. 5,600,000 shares, APIC Co., Ltd. 2,000,000 shares, Namu Invest Co., Ltd. 800,000 shares, Namhwa Corporation 400,000 shares and SLP Co. Ltd. 400,000 shares and individual investors OO Kim for 1,120,000 shares, OO Yoon 2,000,000 shares, OO 400,000 shares, LeeOO 400,000 shares and Seo OO 150,000 shares. The transaction has been approved by the shareholders of the company and is expected to closed on March 4, 2024. The securities are restricted to a hold period.
Reported Earnings • Mar 18Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021)Full year 2022 results: ₩2,201 loss per share (further deteriorated from ₩1,662 loss in FY 2021). Revenue: ₩21.7b (down 26% from FY 2021). Net loss: ₩69.6b (loss widened 38% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 49% per year, which means it has not declined as severely as earnings.
Buying Opportunity • Aug 24Now 25% undervaluedOver the last 90 days, the stock is up 38%. The fair value is estimated to be ₩17,476, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 56%.
お知らせ • Apr 07NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmOn April 5, 2022, NewGLAB Pharma CO.,LTD closed the transaction.
お知らせ • Mar 23NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in fundingOn March 22, 2021, NewGLAB CO.,LTD (KOSDAQ:A214870) closed the transaction.
Reported Earnings • Mar 17Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩54.4b (down 43% from FY 2019). Net loss: ₩22.6b (loss widened 464% from FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 14NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in fundingNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 7 non-guaranteed private convertible bonds with bearer interest with for gross proceeds of KRW 9,230,000,000 on March 12, 2021. The transaction will include participation from Hyun-cheol Noh for KRW 3,230,000,000 and Seong-su Cho for KRW 6,000,000,000. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on March 22, 2024. The bonds are 100% convertible into 699,242 shares, representing 2.28%, at a fixed conversion price of KRW 13,200 per share. The conversion period starts from March 22, 2022 and ends on February 22, 2024. The subscription date is March 12, 2021 and the transaction is expected to close on March 22, 2021. The transaction has been approved by the company's board of directors. The bonds carry a hold period of one year.
Is New 90 Day High Low • Feb 18New 90-day low: ₩10,900The company is down 15% from its price of ₩12,850 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 41% over the same period.
Is New 90 Day High Low • Jan 27New 90-day low: ₩11,850The company is down 12% from its price of ₩13,500 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 57% over the same period.
分析記事 • Dec 22The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Is New 90 Day High Low • Nov 11New 90-day low: ₩12,750The company is down 4.0% from its price of ₩13,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 3.0% over the same period.
お知らせ • Sep 29NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 6 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 35,000,000,000 on September 28, 2020. The transaction will include participation from returning investor DB Financial Investment Co.,Ltd., Investment Arm. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on October 20, 2023. The bonds are 100% convertible into 2,287,432 shares, representing 7.29%, at a fixed conversion price of KRW 15,301 per share. The conversion period starts from October 20, 2021 and ends on September 20, 2023. The subscription date is September 28, 2020 and the transaction is expected to close on October 20, 2020. The transaction has been approved by the company's board of directors.